共 30 条
- [23] Potential of Tenapanor as a Treatment for Chronic Idiopathic Constipation (CIC): A Post Hoc Analysis From the T3MPO-1 and T3MPO-2 Phase 3 Studies for Irritable Bowel Syndrome With Constipation (IBS-C) in Adults AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S393 - S393
- [24] Responsiveness of a Tri-Component Endpoint in Non-Constipation Irritable Bowel Syndrome: Pooled Results from Two Phase 3 Trials, TARGET 1 and TARGET 2 AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S712 - S712
- [25] Impact of Linaclotide Treatment on Work Productivity and Activity Impairment in Adults with Irritable Bowel Syndrome with Constipation: Results from 2 Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials AMERICAN HEALTH AND DRUG BENEFITS, 2014, 7 (05): : 289 - 296
- [26] Rifaximin Treatment Consistently Demonstrated Relief Across Daily Symptoms in Patients with Non-Constipation Irritable Bowel Syndrome: Results from 2 Phase 3 Trials (TARGET 1 and TARGET 2) AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S483 - S484
- [28] The Responsiveness and Validity of a Binary Weekly Recall Question and the Proposed FDA Composite Endpoint as Measures of Daily Symptom Severity in Non-Constipation Irritable Bowel Syndrome: Results of TARGET 1 and TARGET 2 AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S494 - S494